Daniel Perkins

Medicinal cannabis and driving: the intersection of health and road safety policy

Daniel Perkins, Hugh Brophy, Iain McGregor, Paula O'Brien, Julia Quilter, Luke McNamara, Jerome Sarris, Mark Stevenson, Paula Glesson, Justin Sinclair, Paul Dietze

Journal article  |  2021  |  International Journal of Drug Policy

Background Recent shifting attitudes towards the medical use of cannabis has seen legal access pathways established in many jurisd..

Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross-sectional survey

Daniel Perkins, Emerita S Opaleye, Hana Simonova, Jose C Bouso, Luis F Tofoli, Nicole L Galvao-Coelho, Violeta Schubert, Jerome Sarris

Journal article  |  2021  |  DRUG AND ALCOHOL REVIEW

INTRODUCTION: Emerging evidence suggests that psychedelic compounds, including the Amazonian botanical decoction ayahuasca, may pr..

Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers

Jerome Sarris, Daniel Perkins, Lachlan Cribb, Violeta Schubert, Emerita Opaleye, José Carlos Bouso, Milan Scheidegger, Helena Aicher, Hana Simonova, Miroslav Horák, Nicole Leite Galvão-Coelho, David Castle, Luís Fernando Tófoli

Journal article  |  2021  |  Journal of Affective Disorders Reports

Background Ayahuasca is a psychoactive Amazonian brew which has emerging data indicating that it has antidepressant and anxiolytic..

Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm

Daniel Perkins, Jerome Sarris, Susan Rossell, Yvonne Bonomo, David Forbes, Christopher Davey, Daniel Hoyer, Colleen Loo, Greg Murray, Sean Hood, Violeta Schubert, Nicole Leite Galvao-Coelho, Meaghen O'Donnell, Olivia Carter, Paul Liknaitzky, Martin Williams, Dan Siskind, David Penington, Michael Berk, David Castle

Journal article  |  2021  |  AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphet..

Potential and Emerging Therapeutic uses for Psychedelics: panel

Daniel Perkins

Presentation  |  2021

International Medicine in Addiction Conference 2021

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

Nicole L Galvao-Coelho, Wolfgang Marx, Maria Gonzalez, Justin Sinclair, Michael de Manincor, Daniel Perkins, Jerome Sarris

Journal article  |  2021  |  PSYCHOPHARMACOLOGY

RATIONALE: Major depressive disorder is one of the leading global causes of disability, for which the classic serotonergic psyched..

Ayahuasca Healing and Science

Book Chapter  |  2021

Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: results of a large international survey

Daniel Perkins, Violeta Schubert, Hana Simonova, Luís Fernando Tófoli, José Carlos Bouso, Miroslav Horák, Nicole Leite Galvão-Coelho, Jerome Sarris

Journal article  |  2021  |  Frontiers in Pharmacology

Ayahuasca is a traditional plant decoction containing N,N-dimethyltryptamine (DMT) and various β-carbolines including harmine, har..

Medicinal Psychedelics for Addiction Treatment: An Emerging New Paradigm?

Daniel Perkins

Presentation  |  2020

Canadian Society of Addiction Medicine (CSAM) and the International Society of Addiction Medicine (ISAM) annual conference

Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca

Nicole Leite Galvao-Coelho, Ana Cecilia de Menezes Galvao, Raissa Nobrega de Almeida, Fernanda Palhano-Fontes, Isaac Campos Braga, Bruno Lobao Soares, Joao Paulo Maia-de-Oliveira, Daniel Perkins, Jerome Sarris, Draulio Barros de Araujo

Journal article  |  2020  |  JOURNAL OF PSYCHOPHARMACOLOGY

BACKGROUND: Ayahuasca is a traditional Amazon brew and its potential antidepressant properties have recently been explored in scie..